Parkinsons Disease Antipsychotics Delpor Alzheimer’s, Opioid Use Disorder (OUD) Schizophrenia Spasticity zero-order release pharmacokinetics obesity, dementia, Crohn’s disease

New Research on Delpor, Inc.

2 Minute Read

An Executive Informational Overview (EIO) is now available on Delpor, Inc., a closely held clinical-stage biopharmaceutical company developing once-yearly therapeutic products to treat chronic conditions. The 52-page report details the Company's business, its strategy, market opportunities, competition, risks, and more. It is available for download below.

Download Delpor, Inc. Report


Delpor Cover Page

Delpor, Inc. (“Delpor” or “the Company”) is a closely held clinical-stage biopharmaceutical company developing once-yearly therapeutic products to treat chronic conditions. The Company’s unique and patented Prozor™ technology facilitates the release of specific insoluble drugs, such as most antipsychotics, from a non-mechanical (passive) implantable drug delivery device (which is the length of a matchstick). This device is placed under the skin in the abdomen and employs a distinct formulation to allow for the consistent release of medications. The placement procedure for the device is brief, typically lasting only 10 minutes, and is conducted in a physician’s office under local anesthesia. This enhances medication adherence, efficacy, safety, treatment outcomes, and patient quality of life. Delpor’s clinical assets include a 6-12-month formulation of risperidone (DLP-114) for schizophrenia treatment as well as a 6-12-month formulation of naltrexone (DLP-160) for Opioid Use Disorder (OUD) and alcohol dependence treatment. Also in development are earlier stage preclinical candidates, with a 6-month drug formulation of tizanidine (DLP-208) for moderate to severe spasticity, as well as compounds for Parkinson’s, Alzheimer’s, and more. Delpor thinks of its technology as ‘a once-a-year cure for an incurable disease.’


Key Points of Delpor, Inc.

  • Delpor's platform technology offers numerous advantages, including once-yearly dosing, enhanced medication adherence, reversibility, and consistent safety and efficacy. This enables immediate treatment initiation and rapid washout periods, promoting efficient healthcare resource management.

  • Currently marketed long acting injectables (LAIs) enhance medication adherence and are available for risperidone and naltrexone, though they typically last for only up to two months.

  • Delpor has launched its Phase 2b study for DLP-114 in Q2 2024, which could go through year end. The Company then plans to initiate both a registrational Phase III trial and a safety study in parallel, which could be sufficient for product approval.

  • The Company’s regulatory strategy focuses on leveraging the 505(b)(2) regulatory pathway, which offers lower technical risk coupled with significant commercial potential. It also minimizes the need for efficacy trials in most cases.

  • Delpor holds approximately 25 issued patents (9 families) with an additional 30+ pending; some are valid until 2033, while pending ones may extend coverage to 2040.

  • The Company is guided by an experienced management team with a track record of success in pharmaceutical research, development, and commercialization.

  • Delpor has raised approximately $40 million; having been awarded approximately $20 million in non-dilutive funding from the NIH, with the potential for an additional $15 million over the next 12 months. Additionally, the target for the Company’s Series C round is approximately $40 to $60 million.


Visit our Corporate Profile and Investment Highlights pages

for the latest research on Delpor, Inc.




New Research on Delpor, Inc.